In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation

Yoshinobu Kanda, Kumi Oshima, Shinichi Kako, Takahiro Fukuda, Naoyuki Uchida, Koichi Miyamura, Yukio Kondo, Shinji Nakao, Koji Nagafuji, Toshihiro Miyamoto, Mineo Kurokawa, Yasushi Okoshi, Shigeru Chiba, Yasuo Ohashi, Yoichi Takaue, Shuichi Taniguchi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We evaluated the efficacy of in vivo T-cell depletion with alemtuzumab in two prospective studies according to the International Conference on Harmonisation (ICH)-Good Clinical Practice (ICH-GCP) guidelines; one was for patients with aplastic anemia (AA study) and the other was for patients who were undergoing hematopoietic stem cell transplantation (HSCT) from a 2- or 3-antigen-mismatched haploidentical donor (MM study). The final dose of alemtuzumab in these studies was 0.16 mg/kg/day for 6 days. At this dose, all of the 12 and 11 patients in the AA and MM studies, respectively, achieved initial engraftment and the incidences of Grade II-IV acute graft-versus-host disease (GVHD) were 0% and 18%. While cytomegalovirus (CMV) frequently reactivated, none of the patients developed fatal CMV disease. Transplantation-related mortality within 1 year after HSCT was observed in only two and one patients, respectively. The numbers of CD4+ and CD8+ T-cells and T-cell receptor rearrangement excision circles remained low within 1 year after HSCT. These findings suggest that the use of alemtuzumab at this dose in a conditioning regimen enables safe allogeneic HSCT even from a 2- or 3-antigen-mismatched donor. However, the use of a lower dose of alemtuzumab should be explored in future studies to accelerate immune recovery after HSCT.

Original languageEnglish
Pages (from-to)294-300
Number of pages7
JournalAmerican Journal of Hematology
Volume88
Issue number4
DOIs
Publication statusPublished - Apr 1 2013

Fingerprint

Aplastic Anemia
Hematopoietic Stem Cell Transplantation
Transplantation
T-Lymphocytes
Cytomegalovirus
Tissue Donors
Antigens
Graft vs Host Disease
T-Cell Antigen Receptor
Practice Guidelines
alemtuzumab
Prospective Studies
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation : Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. / Kanda, Yoshinobu; Oshima, Kumi; Kako, Shinichi; Fukuda, Takahiro; Uchida, Naoyuki; Miyamura, Koichi; Kondo, Yukio; Nakao, Shinji; Nagafuji, Koji; Miyamoto, Toshihiro; Kurokawa, Mineo; Okoshi, Yasushi; Chiba, Shigeru; Ohashi, Yasuo; Takaue, Yoichi; Taniguchi, Shuichi.

In: American Journal of Hematology, Vol. 88, No. 4, 01.04.2013, p. 294-300.

Research output: Contribution to journalArticle

Kanda, Y, Oshima, K, Kako, S, Fukuda, T, Uchida, N, Miyamura, K, Kondo, Y, Nakao, S, Nagafuji, K, Miyamoto, T, Kurokawa, M, Okoshi, Y, Chiba, S, Ohashi, Y, Takaue, Y & Taniguchi, S 2013, 'In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation', American Journal of Hematology, vol. 88, no. 4, pp. 294-300. https://doi.org/10.1002/ajh.23392
Kanda, Yoshinobu ; Oshima, Kumi ; Kako, Shinichi ; Fukuda, Takahiro ; Uchida, Naoyuki ; Miyamura, Koichi ; Kondo, Yukio ; Nakao, Shinji ; Nagafuji, Koji ; Miyamoto, Toshihiro ; Kurokawa, Mineo ; Okoshi, Yasushi ; Chiba, Shigeru ; Ohashi, Yasuo ; Takaue, Yoichi ; Taniguchi, Shuichi. / In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation : Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. In: American Journal of Hematology. 2013 ; Vol. 88, No. 4. pp. 294-300.
@article{ac292f92473b4776a7d089355b6c5736,
title = "In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation",
abstract = "We evaluated the efficacy of in vivo T-cell depletion with alemtuzumab in two prospective studies according to the International Conference on Harmonisation (ICH)-Good Clinical Practice (ICH-GCP) guidelines; one was for patients with aplastic anemia (AA study) and the other was for patients who were undergoing hematopoietic stem cell transplantation (HSCT) from a 2- or 3-antigen-mismatched haploidentical donor (MM study). The final dose of alemtuzumab in these studies was 0.16 mg/kg/day for 6 days. At this dose, all of the 12 and 11 patients in the AA and MM studies, respectively, achieved initial engraftment and the incidences of Grade II-IV acute graft-versus-host disease (GVHD) were 0{\%} and 18{\%}. While cytomegalovirus (CMV) frequently reactivated, none of the patients developed fatal CMV disease. Transplantation-related mortality within 1 year after HSCT was observed in only two and one patients, respectively. The numbers of CD4+ and CD8+ T-cells and T-cell receptor rearrangement excision circles remained low within 1 year after HSCT. These findings suggest that the use of alemtuzumab at this dose in a conditioning regimen enables safe allogeneic HSCT even from a 2- or 3-antigen-mismatched donor. However, the use of a lower dose of alemtuzumab should be explored in future studies to accelerate immune recovery after HSCT.",
author = "Yoshinobu Kanda and Kumi Oshima and Shinichi Kako and Takahiro Fukuda and Naoyuki Uchida and Koichi Miyamura and Yukio Kondo and Shinji Nakao and Koji Nagafuji and Toshihiro Miyamoto and Mineo Kurokawa and Yasushi Okoshi and Shigeru Chiba and Yasuo Ohashi and Yoichi Takaue and Shuichi Taniguchi",
year = "2013",
month = "4",
day = "1",
doi = "10.1002/ajh.23392",
language = "English",
volume = "88",
pages = "294--300",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation

T2 - Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation

AU - Kanda, Yoshinobu

AU - Oshima, Kumi

AU - Kako, Shinichi

AU - Fukuda, Takahiro

AU - Uchida, Naoyuki

AU - Miyamura, Koichi

AU - Kondo, Yukio

AU - Nakao, Shinji

AU - Nagafuji, Koji

AU - Miyamoto, Toshihiro

AU - Kurokawa, Mineo

AU - Okoshi, Yasushi

AU - Chiba, Shigeru

AU - Ohashi, Yasuo

AU - Takaue, Yoichi

AU - Taniguchi, Shuichi

PY - 2013/4/1

Y1 - 2013/4/1

N2 - We evaluated the efficacy of in vivo T-cell depletion with alemtuzumab in two prospective studies according to the International Conference on Harmonisation (ICH)-Good Clinical Practice (ICH-GCP) guidelines; one was for patients with aplastic anemia (AA study) and the other was for patients who were undergoing hematopoietic stem cell transplantation (HSCT) from a 2- or 3-antigen-mismatched haploidentical donor (MM study). The final dose of alemtuzumab in these studies was 0.16 mg/kg/day for 6 days. At this dose, all of the 12 and 11 patients in the AA and MM studies, respectively, achieved initial engraftment and the incidences of Grade II-IV acute graft-versus-host disease (GVHD) were 0% and 18%. While cytomegalovirus (CMV) frequently reactivated, none of the patients developed fatal CMV disease. Transplantation-related mortality within 1 year after HSCT was observed in only two and one patients, respectively. The numbers of CD4+ and CD8+ T-cells and T-cell receptor rearrangement excision circles remained low within 1 year after HSCT. These findings suggest that the use of alemtuzumab at this dose in a conditioning regimen enables safe allogeneic HSCT even from a 2- or 3-antigen-mismatched donor. However, the use of a lower dose of alemtuzumab should be explored in future studies to accelerate immune recovery after HSCT.

AB - We evaluated the efficacy of in vivo T-cell depletion with alemtuzumab in two prospective studies according to the International Conference on Harmonisation (ICH)-Good Clinical Practice (ICH-GCP) guidelines; one was for patients with aplastic anemia (AA study) and the other was for patients who were undergoing hematopoietic stem cell transplantation (HSCT) from a 2- or 3-antigen-mismatched haploidentical donor (MM study). The final dose of alemtuzumab in these studies was 0.16 mg/kg/day for 6 days. At this dose, all of the 12 and 11 patients in the AA and MM studies, respectively, achieved initial engraftment and the incidences of Grade II-IV acute graft-versus-host disease (GVHD) were 0% and 18%. While cytomegalovirus (CMV) frequently reactivated, none of the patients developed fatal CMV disease. Transplantation-related mortality within 1 year after HSCT was observed in only two and one patients, respectively. The numbers of CD4+ and CD8+ T-cells and T-cell receptor rearrangement excision circles remained low within 1 year after HSCT. These findings suggest that the use of alemtuzumab at this dose in a conditioning regimen enables safe allogeneic HSCT even from a 2- or 3-antigen-mismatched donor. However, the use of a lower dose of alemtuzumab should be explored in future studies to accelerate immune recovery after HSCT.

UR - http://www.scopus.com/inward/record.url?scp=84875622327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875622327&partnerID=8YFLogxK

U2 - 10.1002/ajh.23392

DO - 10.1002/ajh.23392

M3 - Article

C2 - 23450467

AN - SCOPUS:84875622327

VL - 88

SP - 294

EP - 300

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -